Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood thinner may stop autoimmune disease before it starts

NCT ID NCT05098704

Prevention Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests whether clopidogrel, a common blood thinner, can prevent systemic sclerosis (scleroderma) in people who have Raynaud phenomenon and specific antibodies that put them at high risk. About 47% of such individuals develop full scleroderma within five years. Participants take either clopidogrel or a placebo daily for two years, and researchers track how many develop the disease over five years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
clopidogrel
What this could lead to
If it works, this could be the first preventive treatment to stop scleroderma from developing in people with early warning signs.
What could go wrong
This is a mid-stage trial with only 90 participants, so results may not apply widely. Clopidogrel is a blood thinner and carries a risk of bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Jun 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over 18 years old, and less than 85 years old. * Patient with positive AAN (AAN ≥ 1/160) with the following specificity: anti-Scl70 or anti-centromere or anti-RNApolIII, or any other auto-antibodies related to systemic sclerosis * Patient with RP reported by the subject and confirmed by the physician. * Patient affiliated to a health insurance system. * Patient who accepts to participate to the study and signs an inform consent form. Exclusion Criteria: * Patient with an SSc diagnosis according to ACR/EULAR 2013 criteria. * Patient with skin fibrosis at screening. * Patient with antiplatelet treatment at screening. * Patient with contraindications to clopidogrel. * Patient treated by immunosuppressive agent at screening. * Patient treated by anticoagulants at screening * Pregnant or breastfeeding women. * Women of childbearing age refusing effective contraception method during the study treatment (24 months). * Incompetent adults (i.e. Individuals under the protection of a conservator)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Scleroderma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse scleroderma scleroderma systemic sclerosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Scleroderma Systemic sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP - Hôpital Cochin - service de médecine interne

    RECRUITING

    Paris, France

  • CH de Libourne - service de rhumatologie

    RECRUITING

    Libourne, France

  • CH de Mont-de-Marsan - service de rhumatologie

    RECRUITING

    Mont-de-Marsan, France

  • CH de Pau - service de médecine interne

    RECRUITING

    Pau, France

  • CH de la Cote Basque - service de rhumatologie

    RECRUITING

    Bayonne, France

  • CHU de Bordeaux - service de Médecine Interne et Maladies Infectieuses

    NOT_YET_RECRUITING

    Bordeaux, France

  • CHU de Bordeaux - service de rhumatologie

    RECRUITING

    Bordeaux, France

  • CHU de Brest - service de rhumatologie

    RECRUITING

    Brest, France

  • CHU de Grenoble Alpes - service de médecine vasculaire

    RECRUITING

    Grenoble, France

  • CHU de Toulouse - service de médecine interne

    NOT_YET_RECRUITING

    Toulouse, France

  • Service de Médecine Interne et Immunologie Clinique

    NOT_YET_RECRUITING

    Rennes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.